We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength?
Read MoreHide Full Article
Profound Medical (PROF - Free Report) shares rallied 21.7% in the last trading session to close at $6.91. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 16.5% loss over the past four weeks.
The sharp rise in PROF shares can be attributed to Profound Medical’s strong preliminary third-quarter 2026 revenue forecast. The company expects revenues of $9.8 million to $10 million, representing year-over-year growth of 85% to 89% and a sequential increase of 292% to 300%. The projected revenue is also approximately 45% to 47% above the Bloomberg analyst consensus estimate of $6.78 million. Additionally, gross margin is expected to exceed 70%, reflecting continued progress in commercial operations and scale. The stronger-than-expected preliminary results signal improving commercial momentum and could strengthen investor confidence in the company's growth prospects.
This company is expected to post quarterly loss of $0.23 per share in its upcoming report, which represents a year-over-year change of +11.5%. Revenues are expected to be $6 million, up 13.4% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Profound Medical, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on PROF going forward to see if this recent jump can turn into more strength down the road.
Profound Medical is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, Perspective Therapeutics (CATX - Free Report) , finished the last trading session 10.2% higher at $2.71. CATX has returned -17.7% over the past month.
For Perspective Therapeutics, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.24. This represents a change of +31.4% from what the company reported a year ago. Perspective Therapeutics currently has a Zacks Rank of #3 (Hold).
View the Zacks #1 Rank List
Image: Bigstock
Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength?
Profound Medical (PROF - Free Report) shares rallied 21.7% in the last trading session to close at $6.91. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 16.5% loss over the past four weeks.
The sharp rise in PROF shares can be attributed to Profound Medical’s strong preliminary third-quarter 2026 revenue forecast. The company expects revenues of $9.8 million to $10 million, representing year-over-year growth of 85% to 89% and a sequential increase of 292% to 300%. The projected revenue is also approximately 45% to 47% above the Bloomberg analyst consensus estimate of $6.78 million. Additionally, gross margin is expected to exceed 70%, reflecting continued progress in commercial operations and scale. The stronger-than-expected preliminary results signal improving commercial momentum and could strengthen investor confidence in the company's growth prospects.
This company is expected to post quarterly loss of $0.23 per share in its upcoming report, which represents a year-over-year change of +11.5%. Revenues are expected to be $6 million, up 13.4% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Profound Medical, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on PROF going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Profound Medical is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, Perspective Therapeutics (CATX - Free Report) , finished the last trading session 10.2% higher at $2.71. CATX has returned -17.7% over the past month.
For Perspective Therapeutics, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.24. This represents a change of +31.4% from what the company reported a year ago. Perspective Therapeutics currently has a Zacks Rank of #3 (Hold).